Jump to content

Juvenile idiopathic arthritis

From Wikipedia, the free encyclopedia
This article does not deal with the more general topic of childhood arthritis.
Juvenile idiopathic arthritis
Other namesJuvenile rheumatoid arthritis[1]
SpecialtyRheumatology
Differential diagnosisAmplified musculoskeletal pain syndrome[2]
Prevalence3.8-400 in 100,000[3]

Juvenile idiopathic arthritis (JIA), formerly known as juvenile rheumatoid arthritis (JRA),[1] is the most common chronic rheumatic disease of childhood, affecting approximately 3.8 to 400 out of 100,000 children.[3] Juvenile, in this context, refers to disease onset before 16 years of age, while idiopathic refers to a condition with no defined cause, and arthritis is inflammation within the joint.[4]

JIA is an autoimmune, noninfective, inflammatory joint disease, the cause of which remains poorly understood. It is characterised by chronic joint inflammation. JIA is a subset of childhood arthritis, but unlike other, more transient forms of childhood arthritis, JIA persists for at least six weeks, and in some children is a lifelong condition. It differs significantly from forms of arthritis commonly seen in adults (osteoarthritis, rheumatoid arthritis), in terms of cause, disease associations, and prognosis.

The prognosis for children with JIA has improved dramatically over recent decades, particularly with the introduction of biological therapies and a shift towards more aggressive treatment strategies. JIA treatment aims for normal physical and psychosocial functioning, which is an achievable goal for some children with this condition.[5]

Signs and symptoms

[edit]

Arthritis means inflammation within the joint, and is usually recognised by swelling, pain, stiffness and restricted joint movement. Symptoms of JIA vary from individual to individual. This is mainly because JIA is an umbrella term for several subtypes of JIA, which differ according to the number of affected joints, severity of disease and presence or absence of inflammation in other parts of the body.[citation needed]

The key clinical feature in JIA is persistent swelling of the affected joints. Any joint can be affected, but large joints such as the knee and ankle are most commonly involved.[6] Involvement of small joints of the hands and feet is more likely when many joints are affected ('polyarthritis'). Swollen joints may also feel warmer to touch. Swelling may be difficult to detect clinically, especially for joints such as those of the spine, sacroiliac joints, shoulder, hip, and jaw; imaging techniques such as ultrasound or MRI can be very useful to identify the inflammation.[citation needed]

Joint pain is an important symptom, although some children experience minimal or no pain with their arthritis.[7] In these children, the first sign of arthritis may be limping, especially in the morning.[7] Young children are often very good at changing how they move when they have joint pain: they learn to move so that it does not hurt. For example, a child will not push up using an inflamed wrist when climbing, instead putting their weight through the forearm. Morning stiffness that improves later in the day is a common feature (this implies inflammatory-type joint pain versus mechanical-type joint pain).[citation needed]

Swelling and pain usually result in limited movement of the affected joints, for example a knee held bent causing a limp, or being unable to make a full fist. Limited movement may reduce a child's ability to fully participate in activities and undertake usual tasks such as those used for self-care. In some JIA subtypes, more non-specific symptoms of being unwell may be present, such as lethargy, fatigue and poor appetite. Children with systemic JIA usually present with fever and a classic rash and may become quite ill. Late effects of arthritis can include joint contractures (stiff, bent joints with loss of movement) due to joint damage; limb length discrepancies and muscle wasting. Children with JIA vary in the degree to which they are affected by particular symptoms.[citation needed]

Extra-articular

[edit]

Eye disease: JIA is associated with inflammation in the front of the eye (specifically iridocyclitis, a form of chronic anterior uveitis), which affects about one in six children with JIA. Eye involvement occurs most commonly in girls, those with only a few joints involved (oligoarthritis), and those with a positive anti-nuclear antibody (ANA).[8] It usually follows the onset of arthritis or may be detected at the same time as arthritis; occasionally it may occur before joint involvement. The factors linking eye and joint disease are not clearly understood, and the two do not necessarily follow the same course. This complication is usually asymptomatic (without symptoms) and can occur when the joints are not active. It can be detected by an experienced optometrist or ophthalmologist using a slit lamp to look for inflammatory cells in the fluid inside the eye. Most children with JIA will require referral for regular slit lamp screening examinations. Poorly controlled chronic anterior uveitis may result in permanent eye damage, including blindness.[citation needed]

Systemic JIA: children with the Systemic JIA subtype often experience extra-articular manifestations including fever, rash, enlarged lymph nodes, enlarged liver or spleen, serositis and anaemia.[5]

Complications

[edit]

JIA is a chronic disorder, which if neglected, can lead to serious complications. However, with regular follow-up and modern treatments, complications have reduced and outcomes improved. If inflammation is not treated, it can damage the joint, the cartilage and the bone. With the advent of modern therapies, these complications of JIA have become much less common.[9]

Children with JIA may have a reduced overall rate of growth, especially if the disease involves many joints or other body systems.[10] This may be due to a combination of the disease itself, as well as its treatments, particularly corticosteroid use. Paradoxically, limbs where a large joint (such as the knee) is inflamed may have increased growth in the short term, leading to limb-length discrepancy (i.e. one arm or leg is slightly longer than the other). This is due to increased blood supply to the bony growth plates surrounding the inflamed joints. Bone density and bone strength may be reduced through a combination of inflammation, corticosteroid use and reduced physical activity levels.[11] Other musculoskeletal complications may include joint contractures, muscle weakness or muscle wasting.[citation needed]

Uveitis, if left untreated, can result in scarring, glaucoma, cataracts, and even blindness. Regular monitoring allows for early detection and treatment. Steroid eye drops are usually the first line treatment for anterior uveitis. However, other treatments – many of which also treat arthritis (e.g. methotrexate, biologics) – may be required to keep the inflammation under control, and to minimise steroid use over the longer term. Long term steroid use can cause contribute to the development of cataracts.[8]

Macrophage activation syndrome (MAS) is a severe, potentially life-threatening complication that can occur in patients with the systemic subtype of JIA. MAS involves uncontrolled activation of the immune system, sometimes referred to as a 'cytokine storm', which can present with a sepsis-like picture of fever, rash, enlarged liver and spleen, enlarged lymph nodes and cardiorespiratory compromise. It is recognised by a series of characteristic changes in laboratory parameters, including a high ferritin and a paradoxically low erythrocyte sedimentation rate.[citation needed]

Causes

[edit]

The cause of JIA remains unknown. However, the disorder is autoimmune[12] — meaning that the body's own immune system starts to attack and destroy cells and tissues (particularly in the joints) for no apparent reason. The immune system is thought to be provoked by changes in the environment, in combination with mutations in many associated genes[13] and/or other causes of differential expression of genes. Experimental studies have shown that certain mutated viruses may be able to trigger JIA. The disease appears to be more common in girls, and is most common in Caucasians.[14]

The cause of JIA, as the word "idiopathic" suggests, is unknown and an area of active research.[15] Current understanding of JIA suggests that it arises in a genetically susceptible individual due to environmental factors.[16]

Diagnosis

[edit]

The diagnosis of JIA can be difficult, in part because joint pain in children is so common and may be from many causes other than JIA.[17] The characteristic feature of arthritis is joint swelling which is sometimes – but not always – associated with pain. The presence of joint stiffness is another typical feature, particularly when present in the morning and improving with activity.[citation needed]

No single test can confirm a diagnosis of JIA: a combination of presenting signs and symptoms, blood tests, and if necessary medical imaging, is used to make the diagnosis. The blood tests may measure levels of inflammatory markers, as well as the presence of specific immune markers which may include anti-nuclear antibody, HLA-B27, rheumatoid factor and anti–citrullinated protein antibody. These serological markers may be negative in children with JIA, and are often present in healthy children; as such they should not be interpreted in isolation but in the context of the clinical presentation. Many children with JIA have normal blood work. X-rays may be required to ensure that the joint pain and swelling is not from a fracture, cancer, infection, or congenital abnormality. In some cases, fluid from the joint can be aspirated and analysed to assist in making a diagnosis. This test can assist by ruling out other causes of arthritis such as infection.[citation needed]

Classification

[edit]

The current classification system by the International League of Associations for Rheumatology (ILAR) recognizes seven distinct subtypes of JIA, based on their presentation within the first six months: [18] Each subtype has a specific pattern of features as outlined in the table and descriptions below. (The seventh category, not included in the table, is 'Undifferentiated' and includes any patient with JIA who does not meet criteria for other subtypes, or who meets criteria for two or more subtypes).

Oligoarticular Polyarticular (RF negative) Polyarticular (RF positive) Systemic Onset Psoriatic Enthesitis Related Arthritis
% of JIA 50-60 20-30 5-10 10-20 5-15 15
Gender (F:M) 4:1 4:1 9:1 1:1 3:2 1:9
Typical age of onset (years) 2-12 (peak 2–3) 2-12 (peak 2–3) Adolescence Any Mid childhood Adolescence
Joint Pattern Asymmetric; often large joints (knee, ankle, wrist, elbow) Often asymmetric; multiple small and large joints Symmetric; multiple small and large joints Symmetric; multiple small and large joints Asymmetric; small and large joints including hips and especially DIPs Asymmetric; large joints; axial

skeleton

Extra-articular Involvement Uveitis in 20% Painless uveitis (especially if ANA positive) Rheumatoid Nodules Fever, rash, lymphadenopathy, enlarged liver and spleen, Serositis Psoriasis, nail pitting, dactylitis, uveitis in 10%, enthesitis Symptomatic uveitis in 20%, enthesitis, IBD, aortitis

Oligoarticular arthritis

[edit]

Oligoarticular (or pauciarticular) JIA is the most common JIA subtype, and occurs when there are up to four joints involved during the first six months of disease. Two subtypes of oligoarticular arthritis exist: persistent oligoarthritis, where no more than four joints are affected throughout the whole disease course; and extended oligoarthritis, where more than four joints are affected after the first six months of disease. Patients in this subtype are often young, typically aged two to three years and with a female preponderance. The most commonly involved joint is the knee, but other affected joints may include the ankles, wrists, elbows and others. The anti-nuclear antigen (ANA) is positive in up to 80% of patients with oligoarthritis and is associated with a higher risk of associated eye disease (uveitis), particularly in younger patients.[8] The prefixes oligo- and pauci- mean 'few'.[citation needed]

Differential diagnosis

[edit]

There are several other disorders and diseases that present with symptoms like JIA. These causes include, but are not limited to, infectious (for example septic arthritis or osteomyelitis) and post-infectious conditions (reactive arthritis, acute rheumatic fever, and in some geographic areas Lyme disease); hematologic and neoplastic diseases such as leukemia or bony tumors; and other connective tissue diseases (such as systemic lupus erythematosus). For the systemic-onset form of JIA, the differential diagnosis also includes Kawasaki disease and periodic fever syndromes. Some genetic skeletal dysplasias as forms of mucopolysaccharidosis especially type1 Scheie syndrome, progressive pseudorheumatoid dysplasia[19] and multicentric osteolysis, nodulosis, and arthropathy syndrome[20][21] may also mimic JIA, as they may present with joint swelling, joint restriction, stiffness, and pain. The clinical and radiologic overlap between genetic skeletal dysplasias and JIA can be great that molecular analysis may be need to confirm the diagnosis.[19][20][21] Rarely, metabolic diseases, such as Farber disease may also mimic JIA. Patients with Farber disease typically have subcutaneous nodules and a hoarse or weak voice due to growth of nodules on the larynx.

Treatment

[edit]

The major emphasis of the treatment of JIA is helping the child or young person regain normal levels of physical and social functioning by controlling inflammation and extra-articular symptoms. Clinical remission should be the primary target for all patients and treatment should be adjusted until this is achieved.[22] Prompt recognition and management is important as early initiation of therapy increases the likelihood of a response to first-line treatments and of achieving drug-free remission later in life.[23] While overarching consensus treatment guidelines exist, all treatments should be specifically tailored to the individual's needs in discussion with the child or young person and their family.[24][25][26]

Optimal management of JIA requires a multidisciplinary team working to address the needs of an individual patient. Optimising physical and social functioning is accomplished via a two-pronged approach: non-pharmacological strategies such as physical therapies, pain management strategies, and social supports; and the swift use of medication to control inflammation and extra-articular symptoms.[24][27] Early diagnosis and treatment are imperative in helping reduce joint damage and other symptoms, which will help reduce levels of permanent damage leading to long term disability.

Non-pharmacological treatments

[edit]

The optimal approach to treating a child with JIA typically involves a team of medical professionals, which may include (but is not limited to) paediatric rheumatologists, paediatric rheumatology nurses, general paediatricians, general practitioners, adult rheumatologists, physical therapists (PTs), occupational therapists (OTs), podiatrists, psychologists, social workers, pharmacists, ophthalmologists and orthopaedic surgeons. The multi-disciplinary team (MDT) work in conjunction with the child and their parents, the local health service and medical team, the child's school and teachers, community leaders and sports coaches to best support the child and their family.[24]

Together, the team help children to participate as fully and independently as possible in their daily activities by maximising quality of life, maximising function and minimising disruption to the life of the child or young person.

The multidisciplinary team work together to provide the child and their family with support and education about JIA, strategies to promote age-appropriate self-sufficiency and help the child to adapt and adjust to any challenges they face. There are many ways to make daily tasks easier or more manageable. One of the key ways the multidisciplinary team helps children with JIA is to involve them, and their families, in the decision-making process regarding their treatment and rehabilitation.

In young children with JIA, symptoms may result in either delay or regression in developmental milestones such as walking, running or climbing. Upper limb function may also be affected. Members of the multidisciplinary team can perform developmental assessments to identify deficits and guide treatments. The information gathered can be shared with schools and child care facilities.

One of the key ways occupational or physical therapists help young children with JIA is by developing a home therapy program based around play. Exercises are prescribed by both physical therapists and occupational therapists to increase the range a child can move a joint, to strengthen the muscles around a joint, to decrease pain and stiffness and to prevent further limitations in their joint movements. OTs and PTs can provide children with age-appropriate games and activities to allow the children to practice their exercises while playing and socializing with friends. Examples are crafts, swimming, and sports.[28]

Children with JIA may experience challenges with low mood, social interaction, reduced self-confidence and negative self-image. Psychologists, OTs, nurses, social workers and other team members can work with the child and their family to develop strategies to help with these issues. Many JIA support organisations run camps and activities for children with JIA and their families.

Surgery is only used to treat the most severe cases of JIA and is now rarely required.[5]

Physical therapy and exercise

[edit]

Maintaining physical activity is important in all children, but especially for children with JIA. The physical therapist has a role in guiding physical rehabilitation (muscle stretching and strengthening, enhancing joint range of movement, improving balance, etc.); optimising physical functioning; goal-setting; and improving a child's confidence in their own body. They usually work with the child and family to develop a home exercise program which changes over time as the child makes progress.

Arthritis in childhood can be associated with muscle weakness and wasting around the affected joints. It can also lead to low bone density, which may predispose to osteoporosis and fractures in adulthood. Getting regular exercise is an important part of the management of JIA to promote bone and muscle health.[29][30]

There is variation in the exact exercise prescription which best promotes musculoskeletal health whilst reducing fatigue, pain and swelling. Consensus is that children with JIA should be following national public health standards of physical activity and participating in moderate fitness, flexibility, and strengthening exercises, compatible with their abilities and disease restrictions.[31][32]

It is important that – across the week – the exercise is a combination of moderate to vigorous cardiovascular activity (e.g. walking to school, scooting, bike-riding, playing tag, dancing, doing physical education, sports such as basketball or football) and strengthening exercises. Bone strengthening activities build up muscles; by having the muscles push and pull against the bone, the bones themselves get stronger. This can include things like playing on climbing equipment, swinging on monkey-bars, using weights, carrying groceries, skipping or running.

A Cochrane meta-analysis looking at existing RCTs showed in all studies that exercise does not have a detrimental effect on JIA. In fact, there is evidence to show that both low and high-intensity exercise programs result in improved physical function and reduced pain in children with JIA. Guidelines indicate that children with JIA should be encouraged to be physically active and can safely participate in sports without disease exacerbation. Those with actively inflamed joints should limit activities within pain limits, then gradually return to full activity following a disease flare.[31][33]

It may be necessary to use aids like splints or casts to correct biomechanics, but prolonged splinting and casting are now rarely indicated for children with JIA. Following joint injections, children are often advised to 'take it easy', often undertaking one to two days of low activity, although advice around this varies.[34] When a joint (usually a knee) loses range of motion due to prolonged inflammation and pain, a series of plaster casts may be used to gradually extend shortened muscles and restore range. These serial casts are usually applied over days to weeks. Active strengthening and lengthening is used in conjunction with serial casting for optimal results.

Some children may benefit from foot orthotics to support and correct body position and function. Orthotics maintain biomechanical alignment and may reduce discomfort in the legs and back when children participate in physical activities such as sports.

Self-management

[edit]

Pain is the most common and often the most distressing symptom of JIA (although some children with JIA do have joint inflammation without any pain at all). Pain can occur even when children are receiving effective doses of therapies which are managing their underlying disease. A multinational study showed that pain is a predictor of psycho-social well-being. [35] Several studies has also shown that pain at debut is a strong predictor of persistent pain. [36][37][38]

Pain has been found to negatively impact all aspects of quality of life and is associated with a reduction in physical, social and emotional functioning. Children who have higher levels of pain tend to have reduced levels of socialization, school attendance and participation in activities. Increased pain is also correlated with poor sleep and higher fatigue in children with JIA.

The causation of pain in JIA is multifactorial. There are disease-related factors, which relate to the inflammatory process, and anatomical or biomechanical changes that are associated with joint swelling and joint disease. There are psychological factors around dealing with stress, coping with a chronic illness and managing anxiety or depression which can influence the perception of pain and the degree of functional impairment. There are also social factors, which relate to family and peer relationships, parental distress and social and financial supports.

Given the waxing and waning nature of JIA, children's physical abilities, pain and mood can change during periods of flare or remission. Coping with chronic illness during childhood and adolescence is associated with significant stress that can put children at risk for emotional or behavioural distress and can interfere with compliance and adherence to treatment regimes. Managing JIA can be a challenge and it is important to have a toolbox of skills, supports and strategies to draw upon to manage the ups and downs of having a chronic illness.

There are many things that can help children with JIA to grow up to have full and active lives. Having good sleep habits and routines gives a child the best chance of having a refreshing night's sleep and preventing daytime fatigue. This in turn affects concentration, energy levels, memory and mood. Most children need between eight and twelve hours of sleep to feel refreshed, depending on age.[39] Simple strategies like maintaining regular bedtimes, limiting screen time to two hours before bed, having a sleep ritual, avoiding napping during the day, avoiding sugary and caffeinated drinks, having a healthy well-balanced diet, regular exercise and using relaxation techniques can assist in having good night's sleep.

Relaxation techniques can also help to reduce stress, physical tension and be a useful pain management technique. There are a variety of mindfulness strategies which include things like deep breathing, guided-imagery or progressive muscle relaxation. All techniques need to be practiced over time, and it may be necessary to try different combinations to find the method that works best for each individual. These techniques are readily available online, in books, recordings, apps or by seeing a trained professional such as a psychologist.

Education and employment

[edit]

Most children with JIA will be able to consistently attend school, without too many disruptions, even during a disease flare. However, they may require extra help or adaptations in order to do so. Maximising school attendance involves collaboration between the family, the school and the health care team. Prolonged or repeated school absences can have academic, social and emotional implications; except in rare circumstances they are rarely necessary (other than absences for medical or therapy appointments).

These adaptations may include requiring extra time to get between classes or during examinations, using specialised pens or switching to typing rather than handwriting, or minimising the load of heavy books or equipment to be carried in a child's school bag. The exact requirements will vary from child-to-child and will depend on the joints affected. In many instances, the child's treating team will be able to provide specific advice and information for teachers and coaches to smooth the transition back to school.[40] This may take the form of an individualized plan outlining any extra measures that need to be taken at school, what to do in the case of unexpected events or medication administration during school hours. Importantly, JIA can be disruptive not just to the academic aspects of school. It is equally important to optimise school attendance so that the child can maintain friendships and keep up with opportunities to socialize with peers.

As adolescents progress through high school, they may need to factor their current medical status and functional abilities into decisions around their future education and employment plans. Most children with JIA will not be restricted in their study goals or professional aspirations. Students with JIA can usually apply for special arrangements during assessment periods, such as additional time to allow for rest/stretch periods and use of adaptive equipment in some situations. These applications often need to be supported by the treating medical team. The treating team can assist adolescents in finding ways to tell their employers about their condition in a positive way. OTs and social workers can also help teenagers understand their rights as an employee with a chronic illness. It is important that adolescents with JIA understand how to take care of themselves and manage their disease when working full-time or attending higher education. The team will also support those patients who still require medical input through the transition process from paediatric to adult services.

eHealth and mobile Health (mHealth) interventions

[edit]

A new emerging area of support for disease management is through digital technology using eHealth and mobile health (mHealth) interventions. These interventions have to potential to support the development of self-management skills, or assist the healthcare team to monitor symptoms. For JIA, current studies have focused on the health issues pain, health related quality of life, physical activity and disease management. Children and adolescents have used these interventions through a range of devices including computers, laptops, personal digital assistants, multimedia-players, and wearable accelerometers synchronised to smart phone. This allows access to these interventions from home. Early usability studies have been gaining positive feedback by children and adolescents. They are familiar with this type of technology and report liking these interventions. However further research is still needed to understand their full potential in supporting children and adolescents living with complex needs.[41]

Prognosis

[edit]

At the time of receiving a JIA diagnosis, children and their families often have many questions regarding prognosis. Recent therapeutic advances in the management of JIA have made inactive disease and clinical remission achievable goals for the majority of children with access to modern treatments. Clinical remission can be defined as the absence of signs and symptoms of inflammatory disease activity, including extra-articular manifestations of the disease. Differentiating subtypes of JIA helps to target treatment and leads to more positive outcomes, however subtype is not the only predictor of JIA outcome. Poor prognostic factors include arthritis of the hip, cervical spine, ankles or wrists; prolonged elevation of inflammatory markers; and radiographic evidence of joint damage including erosions or joint space narrowing. Patients with RF-positive polyarthritis often have worse outcomes associated with more aggressive disease. Despite this, the probability of this subgroup achieving inactive disease at least once within five years was shown to be 90% in a large Canadian study.[42] Research is currently being undertaken into clinical prediction models to allow earlier identification of children who are likely to have a worse prognosis.[43] Compliance with therapy, especially medication, has a positive correlation with disease outcome.

Research into specific JIA biomarkers is currently underway, with the goal of forming more personalized treatment plans, reducing medication side effects and improving remission rates. Current areas of investigation include clinical, protein, genetic and radiological markers, amongst others.[44]

Children with JIA demonstrate similar levels of depression and anxiety to children with other chronic diseases; however, causality has not been established. The unpredictable and undulating course of JIA disease activity and the need for ongoing procedural interventions may contribute.

It has been previously suggested that children with JIA are at an increased risk of malignancies when being treated with anti-TNF therapy. More recent data has not confirmed this association: it is thought that the disease itself is linked with a slightly higher background risk of malignancy. Ongoing data analysis on large patient populations continues in this area.[45]

Epidemiology

[edit]

Juvenile Idiopathic Arthritis is the most common, chronic rheumatic disease of childhood. In high-income countries, yearly incidence has been estimated at 2–20 cases per 100,000 population; prevalence in these areas is estimated at 16–150 cases per 100,000 population.[46] However, there is also a suggestion that these numbers underestimate disease prevalence: one community-based survey of school children in Western Australia reported a prevalence of 400 per 100,000.[47] Overall prevalence is often summarised as one per thousand children.[48][49][40][50]

Incidence and prevalence data vary across different population and ethnic groups, with lower overall prevalence in Afro-Caribbean and Asian populations. There are also ethnic differences in the frequency of JIA subtypes: for example, oligoarthritis is the most common subtype in European populations, whilst polyarticular disease predominates in many other countries including Costa Rica, India, New Zealand, and South Africa.[51]

There are differences in age of onset, gender and disease outcomes based on JIA subtype: these are outlined in the table above.

Terminology

[edit]

The terminology used to describe JIA is evolving, and each term has some limitations.

Previous terminology included Juvenile Rheumatoid Arthritis and Juvenile Chronic Arthritis. These terms were replaced in 1997 with the release of the revised ILAR (International League of Associations for Rheumatology) classification criteria.[52]

There is currently an international movement underway to further revise the classification criteria for JIA, although this is in a preliminary phase.[53]

MeSH uses "juvenile arthritis" as the primary entry, and uses "idiopathic", "chronic" and "rheumatoid" in alternate entries.[54]

Society

[edit]

Some famous people with this condition are:

References

[edit]
  1. ^ a b "Juvenile Rheumatoid Arthritis (JRA)". WebMD.
  2. ^ "Amplified Musculoskeletal Pain Syndrome (AMPS)". Children's Health.
  3. ^ a b Thierry, S; Fautrel, B; Lemelle, I; Guellemin, F (March 2014). "Prevalence and incidence of juvenile idiopathic arthritis: A systematic review". Joint Bone Spine. 81 (2): 112–117. doi:10.1016/j.jbspin.2013.09.003. PMID 24210707.
  4. ^ Prakken, B; Albani, S; Martini, A (18 June 2021). "Juvenile idiopathic arthritis". Lancet. 377 (9783): 2138–49. doi:10.1016/S0140-6736(11)60244-4. PMID 21684384. S2CID 202802455.
  5. ^ a b c Giancane, Gabriella; Consolaro, Alessandro; Lanni, Stefano; Davì, Sergio; Schiappapietra, Benedetta; Ravelli, Angelo (12 August 2016). "Juvenile Idiopathic Arthritis: Diagnosis and Treatment". Rheumatology and Therapy. 3 (2): 187–207. doi:10.1007/s40744-016-0040-4. PMC 5127964. PMID 27747582.
  6. ^ Hemke, Robert; Nusman, Charlotte M.; van der Heijde, Désirée M. F. M.; Doria, Andrea S.; Kuijpers, Taco W.; Maas, Mario; van Rossum, Marion A. J. (14 August 2014). "Frequency of joint involvement in juvenile idiopathic arthritis during a 5-year follow-up of newly diagnosed patients: implications for MR imaging as outcome measure". Rheumatology International. 35 (2): 351–357. doi:10.1007/s00296-014-3108-x. PMID 25119829. S2CID 859955.
  7. ^ a b "American College of Rheumatology: Juvenile Arthritis". www.rheumatology.org. Retrieved 13 March 2020.
  8. ^ a b c Sen, Ethan S.; Dick, Andrew D.; Ramanan, Athimalaipet V. (31 March 2015). "Uveitis associated with juvenile idiopathic arthritis". Nature Reviews Rheumatology. 11 (6): 338–348. doi:10.1038/nrrheum.2015.20. PMID 25825278. S2CID 12096252.
  9. ^ Foster, H.; Rapley, T.; May, C. (17 November 2009). "Juvenile idiopathic arthritis: improved outcome requires improved access to care". Rheumatology. 49 (3): 401–403. doi:10.1093/rheumatology/kep347. PMID 19920094.
  10. ^ Bechtold, Susanne; Simon, Dominique (24 April 2014). "Growth abnormalities in children and adolescents with juvenile idiopathic arthritis". Rheumatology International. 34 (11): 1483–1488. doi:10.1007/s00296-014-3022-2. PMID 24760485. S2CID 10546793.
  11. ^ Burnham, Jon M.; Shults, Justine; Dubner, Sarah E.; Sembhi, Harjeet; Zemel, Babette S.; Leonard, Mary B. (August 2008). "Bone density, structure, and strength in juvenile idiopathic arthritis: Importance of disease severity and muscle deficits". Arthritis & Rheumatism. 58 (8): 2518–2527. doi:10.1002/art.23683. PMC 2705769. PMID 18668565.
  12. ^ Prahalad S, Glass DN (2002). "Is juvenile rheumatoid arthritis/juvenile idiopathic arthritis different from rheumatoid arthritis?". Arthritis Research. 4 (Suppl 3): 303–310. doi:10.1186/ar594. PMC 3273047.
  13. ^ Hinks A, Cobb J, Marion MC, Prahalad S, Sudman M, Bowes J, et al. (June 2013). "Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis". Nature Genetics. 45 (6): 664–9. doi:10.1038/ng.2614. PMC 3673707. PMID 23603761.
  14. ^ "Juvenile Arthritis". Retrieved 2010-04-19.
  15. ^ Phelan JD, Thompson SD (September 2006). "Genomic progress in pediatric arthritis: recent work and future goals". Current Opinion in Rheumatology. 18 (5): 482–9. doi:10.1097/01.bor.0000240359.30303.e4. PMID 16896287. S2CID 7356346.
  16. ^ Førre O, Smerdel A (2002). "Genetic epidemiology of juvenile idiopathic arthritis". Scandinavian Journal of Rheumatology. 31 (3): 123–8. doi:10.1080/713798345. PMID 12195624.
  17. ^ Balan, Suma (9 January 2016). "Approach to Joint Pain in Children". The Indian Journal of Pediatrics. 83 (2): 135–139. doi:10.1007/s12098-015-2016-8. PMID 26747081. S2CID 207388664.
  18. ^ Petty, RE; Southwood, TR; Manners, P; Baum, J; Glass, DN; Goldenberg, J; He, X; Maldonado-Cocco, J; Orozco-Alcala, J; Prieur, AM; Suarez-Almazor, ME; Woo, P; International League of Associations for, Rheumatology. (February 2004). "International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001". The Journal of Rheumatology. 31 (2): 390–2. PMID 14760812.
  19. ^ a b Torreggiani, S; Torcoletti, M; Campos-Xavier, B; Baldo, F; Agostoni, C; Superti-Furga, A; Filocamo, G (March 2019). "Progressive pseudorheumatoid dysplasia: a rare childhood disease". Rheumatology International. 39 (3): 441–452. doi:10.1007/s00296-018-4170-6. PMID 30327864. S2CID 53528751.
  20. ^ a b Elsebaie, H; Mansour, MA; Elsayed, SM; Mahmoud, S; El-Sobky, TA (December 2021). "Multicentric Osteolysis, Nodulosis, and Arthropathy in two unrelated children with matrix metalloproteinase 2 variants: Genetic-skeletal correlations". Bone Reports. 15: 101106. doi:10.1016/j.bonr.2021.101106. PMC 8283316. PMID 34307793.
  21. ^ a b de Vos, IJHM; Wong, ASW; Welting, TJM; Coull, BJ; van Steensel, MAM (August 2019). "Multicentric osteolytic syndromes represent a phenotypic spectrum defined by defective collagen remodeling" (PDF). American Journal of Medical Genetics. Part A. 179 (8): 1652–1664. doi:10.1002/ajmg.a.61264. PMID 31218820. S2CID 195186523.
  22. ^ Ravelli, Angelo; Consolaro, Alessandro; Horneff, Gerd; Laxer, Ronald M; Lovell, Daniel J; Wulffraat, Nico M; Akikusa, Jonathan D; Al-Mayouf, Sulaiman M; Antón, Jordi; Avcin, Tadej; Berard, Roberta A; Beresford, Michael W; Burgos-Vargas, Ruben; Cimaz, Rolando; De Benedetti, Fabrizio; Demirkaya, Erkan; Foell, Dirk; Itoh, Yasuhiko; Lahdenne, Pekka; Morgan, Esi M; Quartier, Pierre; Ruperto, Nicolino; Russo, Ricardo; Saad-Magalhães, Claudia; Sawhney, Sujata; Scott, Christiaan; Shenoi, Susan; Swart, Joost F; Uziel, Yosef; Vastert, Sebastiaan J; Smolen, Josef S (11 April 2018). "Treating juvenile idiopathic arthritis to target: recommendations of an international task force". Annals of the Rheumatic Diseases. 77 (6): annrheumdis-2018-213030. doi:10.1136/annrheumdis-2018-213030. hdl:11449/171016. PMID 29643108. S2CID 4830829.
  23. ^ Minden, Kirsten; Horneff, Gerd; Niewerth, Martina; Seipelt, Eva; Aringer, Martin; Aries, Peer; Foeldvari, Ivan; Haas, Johannes-Peter; Klein, Ariane; Tatsis, Stefanie; Tenbrock, Klaus; Zink, Angela; Klotsche, Jens (28 March 2019). "Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood". Arthritis Care & Research. 71 (4): 471–481. doi:10.1002/acr.23709. PMID 30044538. S2CID 51715770.
  24. ^ a b c Davies, K.; Cleary, G.; Foster, H.; Hutchinson, E.; Baildam, E. (19 February 2010). "BSPAR Standards of Care for children and young people with juvenile idiopathic arthritis". Rheumatology. 49 (7): 1406–1408. doi:10.1093/rheumatology/kep460. PMID 20173199.
  25. ^ Ringold, Sarah; Angeles-Han, Sheila T.; Beukelman, Timothy; Lovell, Daniel; Cuello, Carlos A.; Becker, Mara L.; Colbert, Robert A.; Feldman, Brian M.; Ferguson, Polly J.; Gewanter, Harry; Guzman, Jaime; Horonjeff, Jennifer; Nigrovic, Peter A.; Ombrello, Michael J.; Passo, Murray H.; Stoll, Matthew L.; Rabinovich, C. Egla; Schneider, Rayfel; Halyabar, Olha; Hays, Kimberly; Shah, Amit Aakash; Sullivan, Nancy; Szymanski, Ann Marie; Turgunbaev, Marat; Turner, Amy; Reston, James (25 April 2019). "2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis". Arthritis Care & Research. 71 (6): 717–734. doi:10.1002/acr.23870. PMC 6561125. PMID 31021516.
  26. ^ Cellucci, Tania; Guzman, Jaime; Petty, Ross E.; Batthish, Michelle; Benseler, Susanne M.; Ellsworth, Janet E.; Houghton, Kristin M.; LeBlanc, Claire M.A.; Huber, Adam M.; Luca, Nadia; Schmeling, Heinrike; Shiff, Natalie J.; Soon, Gordon S.; Tse, Shirley M.L. (1 October 2016). "Management of Juvenile Idiopathic Arthritis 2015: A Position Statement from the Pediatric Committee of the Canadian Rheumatology Association". The Journal of Rheumatology. 43 (10): 1773–1776. doi:10.3899/jrheum.160074. PMID 27698103.
  27. ^ Ringold, Sarah; Angeles-Han, Sheila T.; Beukelman, Timothy; Lovell, Daniel; Cuello, Carlos A.; Becker, Mara L.; Colbert, Robert A.; Feldman, Brian M.; Ferguson, Polly J.; Gewanter, Harry; Guzman, Jaime; Horonjeff, Jennifer; Nigrovic, Peter A.; Ombrello, Michael J.; Passo, Murray H.; Stoll, Matthew L.; Rabinovich, C. Egla; Schneider, Rayfel; Halyabar, Olha; Hays, Kimberly; Shah, Amit Aakash; Sullivan, Nancy; Szymanski, Ann Marie; Turgunbaev, Marat; Turner, Amy; Reston, James (25 April 2019). "2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis". Arthritis Care & Research. 71 (6): 717–734. doi:10.1002/acr.23870. PMC 6561125. PMID 31021516.
  28. ^ De Monte R, Rodger S, Jones F, Broderick S (August 2009). "Living with juvenile idiopathic arthritis: children's experiences of participating in home exercise programmes". British Journal of Occupational Therapy. 72 (8): 357–65. doi:10.1177/030802260907200806. S2CID 72219322.
  29. ^ Stagi, Stefano; Cavalli, Loredana; Signorini, Carla; Bertini, Federico; Cerinic, Marco; Brandi, Maria; Falcini, Fernanda (2014). "Bone mass and quality in patients with juvenile idiopathic arthritis: longitudinal evaluation of bone-mass determinants by using dual-energy x-ray absorptiometry, peripheral quantitative computed tomography, and quantitative ultrasonography". Arthritis Research & Therapy. 16 (2): R83. doi:10.1186/ar4525. PMC 4060444. PMID 24684763.
  30. ^ Long, Amy R; Rouster-Stevens, Kelly A (March 2010). "The role of exercise therapy in the management of juvenile idiopathic arthritis". Current Opinion in Rheumatology. 22 (2): 213–217. doi:10.1097/BOR.0b013e328335d1a2. PMID 20010296. S2CID 25442812.
  31. ^ a b Philpott, John F; Houghton, Kristin; Luke, Anthony (May 2010). "Physical Activity Recommendations for Children With Specific Chronic Health Conditions: Juvenile Idiopathic Arthritis, Hemophilia, Asthma, and Cystic Fibrosis". Clinical Journal of Sport Medicine. 20 (3): 167–172. doi:10.1097/JSM.0b013e3181d2eddd. PMC 2866314. PMID 20445355.
  32. ^ "Time to Move: Juvenile Idiopathic Arthritis" (PDF). Arthritis Australia. Retrieved 17 March 2020.
  33. ^ Takken, Tim; Van Brussel, Marco; Engelbert, Raoul H.H.; van der Net, Janjaap J; Kuis, Wietse; Helders, Paul PJM (23 April 2008). "Exercise therapy in juvenile idiopathic arthritis". Cochrane Database of Systematic Reviews. 2010 (2): CD005954. doi:10.1002/14651858.CD005954.pub2. PMC 8903819. PMID 18425929.
  34. ^ Gotte, Alisa (May 2009). "Intra-articular corticosteroids in the treatment of juvenile idiopathic arthritis: Safety, efficacy, and features affecting outcome. A comprehensive review of the literature". Open Access Rheumatology: Research and Reviews. 1: 37–49. doi:10.2147/oarrr.s5103. PMC 5074724. PMID 27789980.
  35. ^ Gutierrez-Suarez, R.; Pistorio, A.; Cespedes Cruz, A.; Norambuena, X.; Flato, B.; Rumba, I.; Harjacek, M.; Nielsen, S.; Susic, G.; Mihaylova, D.; Huemer, C.; Melo-Gomes, J.; Andersson-Gare, B.; Balogh, Z.; De Cunto, C. (2006-07-28). "Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study". Rheumatology. 46 (2): 314–320. doi:10.1093/rheumatology/kel218. ISSN 1462-0324.
  36. ^ Rashid, Amir; Cordingley, Lis; Carrasco, Roberto; Foster, Helen E; Baildam, Eileen M; Chieng, Alice; Davidson, Joyce E; Wedderburn, Lucy R; Ioannou, Yiannis; McErlane, Flora; Verstappen, Suzanne M M; Hyrich, Kimme L; Thomson, Wendy (May 2018). "Patterns of pain over time among children with juvenile idiopathic arthritis". Archives of Disease in Childhood. 103 (5): 437–443. doi:10.1136/archdischild-2017-313337. ISSN 0003-9888. PMC 5916104. PMID 29175824.
  37. ^ Thastum, Mikael; Herlin, Troels (2011). "Pain-specific Beliefs and Pain Experience in Children with Juvenile Idiopathic Arthritis: A Longitudinal Study". The Journal of Rheumatology. 38 (1): 155–160. doi:10.3899/jrheum.091375. ISSN 0315-162X.
  38. ^ Arnstad, Ellen Dalen; Rypdal, Veronika; Peltoniemi, Suvi; Herlin, Troels; Berntson, Lillemor; Fasth, Anders; Nielsen, Susan; Glerup, Mia; Ekelund, Maria; Zak, Marek; Aalto, Kristiina; Nordal, Ellen; Romundstad, Pål Richard; Rygg, Marite; the Nordic Study Group of Pediatric Rheumatology (July 2019). "Early Self‐Reported Pain in Juvenile Idiopathic Arthritis as Related to Long‐Term Outcomes: Results From the Nordic Juvenile Idiopathic Arthritis Cohort Study". Arthritis Care & Research. 71 (7): 961–969. doi:10.1002/acr.23715. ISSN 2151-464X.
  39. ^ "How Much Sleep Do Babies and Kids Need? | National Sleep Foundation". www.sleepfoundation.org. 24 September 2020.
  40. ^ a b "Teacher's guide to JIA". Arthritis Australia.
  41. ^ Butler, Sonia; Sculley, Dean; Santos, Derek Santos; Fellas, Antoni; Gironès, Xavier; Singh-Grewal, Davinder; Coda, Andrea (2020). "Usability of e Health and Mobile Health Interventions by Young People Living with Juvenile Idiopathic Arthritis: Systematic Review". JMIR Pediatrics and Parenting. 3 (2): e15833. doi:10.2196/15833. PMC 7738264. PMID 33258786.
  42. ^ Guzman, Jaime; Oen, Kiem; Tucker, Lori B; Huber, Adam M; Shiff, Natalie; Boire, Gilles; Scuccimarri, Rosie; Berard, Roberta; Tse, Shirley M L; Morishita, Kimberly; Stringer, Elizabeth; Johnson, Nicole; Levy, Deborah M; Duffy, Karen Watanabe; Cabral, David A; Rosenberg, Alan M; Larché, Maggie; Dancey, Paul; Petty, Ross E; Laxer, Ronald M; Silverman, Earl; Miettunen, Paivi; Chetaille, Anne-Laure; Haddad, Elie; Houghton, Kristin; Spiegel, Lynn; Turvey, Stuart E; Schmeling, Heinrike; Lang, Bianca; Ellsworth, Janet; Ramsey, Suzanne; Bruns, Alessandra; Campillo, Sarah; Benseler, Susanne; Chédeville, Gaëlle; Schneider, Rayfel; Yeung, Rae; Duffy, Ciarán M (October 2015). "The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort". Annals of the Rheumatic Diseases. 74 (10): 1854–1860. doi:10.1136/annrheumdis-2014-205372. PMID 24842571. S2CID 44612457.
  43. ^ Henrey, Andrew; Rypdal, Veronika; Rypdal, Martin; Loughin, Thomas; Nordal, Ellen; Guzman, Jaime (15 January 2020). "Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort". Arthritis Research & Therapy. 22 (1): 10. doi:10.1186/s13075-019-2091-8. PMC 6964007. PMID 31941530.
  44. ^ Duurland, Chantal L.; Wedderburn, Lucy R. (21 January 2014). "Current Developments in the Use of Biomarkers for Juvenile Idiopathic Arthritis". Current Rheumatology Reports. 16 (3): 406. doi:10.1007/s11926-013-0406-3. PMC 3930839. PMID 24445961.
  45. ^ Beukelman, Timothy; Xie, Fenglong; Chen, Lang; Horton, Daniel B; Lewis, James D; Mamtani, Ronac; Mannion, Melissa M; Saag, Kenneth G; Curtis, Jeffrey R (July 2018). "Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors". Annals of the Rheumatic Diseases. 77 (7): 1012–1016. doi:10.1136/annrheumdis-2017-212613. PMC 6094159. PMID 29440001.
  46. ^ Prakken, Berent; Albani, Salvatore; Martini, Alberto (June 2011). "Juvenile idiopathic arthritis". The Lancet. 377 (9783): 2138–2149. doi:10.1016/S0140-6736(11)60244-4. PMID 21684384. S2CID 202802455.
  47. ^ Manners, PJ; Diepeveen, DA (July 1996). "Prevalence of juvenile chronic arthritis in a population of 12-year-old children in urban Australia". Pediatrics. 98 (1): 84–90. doi:10.1542/peds.98.1.84. PMID 8668417. S2CID 245080592.
  48. ^ Harris, Julia G.; Kessler, Elizabeth A.; Verbsky, James W. (21 April 2013). "Update on the Treatment of Juvenile Idiopathic Arthritis". Current Allergy and Asthma Reports. 13 (4): 337–346. doi:10.1007/s11882-013-0351-2. PMC 3729726. PMID 23605168.
  49. ^ "Juvenile Idiopathic Arthritis" (PDF). RACGP.
  50. ^ "Rheumatology: Information on JIA for young people". www.rch.org.au.
  51. ^ Ravelli, Angelo; Martini, Alberto (March 2007). "Juvenile idiopathic arthritis". The Lancet. 369 (9563): 767–778. doi:10.1016/S0140-6736(07)60363-8. PMID 17336654. S2CID 53265788.
  52. ^ Petty, RE; Southwood, TR; Baum, J; Bhettay, E; Glass, DN; Manners, P; Maldonado-Cocco, J; Suarez-Almazor, M; Orozco-Alcala, J; Prieur, AM (October 1998). "Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997". The Journal of Rheumatology. 25 (10): 1991–4. PMID 9779856.
  53. ^ Martini, Alberto; Ravelli, Angelo; Avcin, Tadej; Beresford, Michael W.; Burgos-Vargas, Ruben; Cuttica, Ruben; Ilowite, Norman T.; Khubchandani, Raju; Laxer, Ronald M.; Lovell, Daniel J.; Petty, Ross E.; Wallace, Carol A.; Wulffraat, Nico M.; Pistorio, Angela; Ruperto, Nicolino (February 2019). "Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus". The Journal of Rheumatology. 46 (2): 190–197. doi:10.3899/jrheum.180168. PMID 30275259.
  54. ^ "MeSH Browser". meshb.nlm.nih.gov.
  55. ^ Azevedo, Valderílio F.; Diaz-Torne, Cesar (December 2008). "The Arthritis of Antoni Gaudí". Journal of Clinical Rheumatology. 14 (6): 367–369. doi:10.1097/RHU.0b013e31818ee74c. PMID 19060668.
  56. ^ Courtney, Paula (April 19, 2017). "Clark Middleton (The Blacklist, The Path) talks about his life & career". Absolute Music Chat. Retrieved September 28, 2021.
  57. ^ Cliff, Aimee (November 27, 2018). "Clairo IRL". Dazed. Archived from the original on January 14, 2021. Retrieved July 13, 2022.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Juvenile_idiopathic_arthritis&oldid=1253024659"